Aroa Biosurgery Ltd
ASX:ARX
Intrinsic Value
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. [ Read More ]
The intrinsic value of one
ARX
stock under the Base Case scenario is
1.08
AUD.
Compared to the current market price of 0.52 AUD,
Aroa Biosurgery Ltd
is
Undervalued by 52%.
Aroa Biosurgery Ltd's market capitalization is 178.6m AUD.
ARX stock price is 0.52 AUD.
ARX stock price (0.52 AUD) is 52% less than its Intrinsic Value (1.08 AUD).
ARX has upside potential of 101% compared to the average analyst price target.
Open Wall St Estimates
ARX's Revenue has grown by an exceptional 29% over the past 12 months.
ARX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -25% to -11%, and is approaching profitability.
ARX's Revenue is forecast to grow at a rate of 21% per year over the next 3 years.
ARX's ROE (Return on Equity) for the past 12 months is negative and is equal to -8%.
ARX's ROE (Return on Equity) has significantly increased in the last 3 years from -33% to -8%, and is approaching profitability.
ARX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -11%.
ARX has negative Operating Income for the last twelve months.
ARX has negative Net Income for the last twelve months.
ARX has positive Gross Profit for the last twelve months.
ARX has negative three-year average ROE (Return on Equity): -11%. The company is not efficient at transforming stockholders' equity into net income.
ARX has negative Free Cash Flow for the last twelve months.
ARX has negative three-year average ROIC (Return on Invested Capital): -15%. The company is not efficient at using invested capital to generate operating income.
ARX's D/E (Debt to Equity) is very low and is equal to 0.06.
ARX's short-term assets (73m NZD) exceed its short-term liabilties (9m NZD).
ARX's long-term assets (113m NZD) exceed its long-term liabilties (15m NZD).
ARX has negative Net Debt. This means that the company has more cash and short-term investments (35m NZD) than debt (6m NZD).
ARX's Altman Z-Score is very high and is equal to 10.55.
Valuation Backtest
Aroa Biosurgery Ltd
Run backtest to discover the historical profit from buying and selling
ARX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Aroa Biosurgery Ltd
Balance Sheet Decomposition
Aroa Biosurgery Ltd
| Current Assets | 73.2m |
| Cash & Short-Term Investments | 35m |
| Receivables | 30.2m |
| Other Current Assets | 8m |
| Non-Current Assets | 39.4m |
| PP&E | 21.2m |
| Intangibles | 18m |
| Other Non-Current Assets | 200k |
| Current Liabilities | 9.3m |
| Accounts Payable | 3m |
| Accrued Liabilities | 3.6m |
| Other Current Liabilities | 2.7m |
| Non-Current Liabilities | 6.1m |
| Long-Term Debt | 5.9m |
| Other Non-Current Liabilities | 200k |
Earnings Waterfall
Aroa Biosurgery Ltd
|
Revenue
|
65.9m
NZD
|
|
Cost of Revenue
|
-10.2m
NZD
|
|
Gross Profit
|
55.7m
NZD
|
|
Operating Expenses
|
-63.3m
NZD
|
|
Operating Income
|
-7.6m
NZD
|
|
Other Expenses
|
-670k
NZD
|
|
Net Income
|
-8.3m
NZD
|
Free Cash Flow Analysis
Aroa Biosurgery Ltd
What is Free Cash Flow?
ARX Profitability Score
Profitability Due Diligence
Aroa Biosurgery Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Aroa Biosurgery Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
ARX Solvency Score
Solvency Due Diligence
Aroa Biosurgery Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Aroa Biosurgery Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARX Price Targets Summary
Aroa Biosurgery Ltd
According to Wall Street analysts, the average 1-year price target for
ARX
is 1.05 AUD
with a low forecast of 0.94 AUD and a high forecast of 1.26 AUD.
Shareholder Return
ARX Price
Aroa Biosurgery Ltd
| Average Annual Return | 148.1% |
| Standard Deviation of Annual Returns | 308.46% |
| Max Drawdown | -100% |
| Market Capitalization | 178.6m AUD |
| Shares Outstanding | 344 208 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Aroa Biosurgery Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
Contact
IPO
Employees
Officers
The intrinsic value of one
ARX
stock under the Base Case scenario is
1.08
AUD.
Compared to the current market price of 0.52 AUD,
Aroa Biosurgery Ltd
is
Undervalued by 52%.
You don't have any saved screeners yet
